SPR720 (phosphate prodrug of SPR719)

Synonym(s): Fobrepodacin

Class: Bacterial topoisomerase inhibitor

Details of activity:	Active against Mycobacterium avium, Mycobacterium kansasii, Mycobacterium ulcerans, Mycobacterium marinum, and Mycobacterium chimaera; DNA gyrase inhibitor (targeting GyrB subunit)
Description:	Synthetic compound; for nontuberculous mycobacterial pulmonary infection; rapidly converted to the active moiety SPR719 in vivo
Institute where first reported:	Spero Therapeutics, Inc., Cambridge, Massachusetts, USA
Year first mentioned:	2018
Highest developmental phase:	Phase 2 (NCT05496374)
Development status:	Active (as of 2024)

Chemical structure(s):
Canonical SMILES:	CCNC(=O)NC1=NC2=C([C@H]3CCCO3)C(=C(C=C2N1)C4=CN=C(C(C)(C)OP(=O)(O)O)N=C4)F
Isomeric SMILES:	CCNC(=O)NC1=NC2=C(N1)C=C(C(=C2[C@H]3CCCO3)F)C4=CN=C(N=C4)C(C)(C)OP(=O)(O)O
InChI:	InChI=1S/C21H26FN6O6P/c1-4-23-20(29)28-19-26-13-8-12(16(22)15(17(13)27-19)14-6-5-7-33-14)11-9-24-18(25-10-11)21(2,3)34-35(30,31)32/h8-10,14H,4-7H2,1-3H3,(H2,30,31,32)(H3,23,26,27,28,29)/t14-/m1/s1
InChI Key:	COTQDURISRILOR-CQSZACIVSA-N
Structure link:	https://pubchem.ncbi.nlm.nih.gov/compound/68108988

External links:
Main Source:	https://journals.asm.org/doi/10.1128/aac.01208-21